CPC C07K 16/2878 (2013.01) [A61K 39/001102 (2018.08); A61K 39/3955 (2013.01); A61P 35/00 (2018.01); C07K 16/2818 (2013.01); A61K 45/06 (2013.01); A61K 2039/505 (2013.01); C07K 2317/33 (2013.01); C07K 2317/52 (2013.01); C07K 2317/55 (2013.01); C07K 2317/56 (2013.01); C07K 2317/75 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)] | 18 Claims |
1. A method for treating a cancer in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of an antibody, or antigen-binding fragment thereof, that binds to an extracellular domain of human CD137, wherein the antibody or antigen-binding fragment comprises a heavy chain variable region and a light chain variable region,
wherein:
(i) the heavy chain variable region comprises an HVR-H1 comprising the amino acid sequence of SEQ ID NO:731, an HVR-H2 comprising the amino acid sequence of SEQ ID NO:755, and an HVR-H3 comprising the amino acid sequence of SEQ ID NO:779; and
(ii) the light chain variable region comprises an HVR-L1 comprising the amino acid sequence of SEQ ID NO:803, an HVR-L2 comprising the amino acid sequence of SEQ ID NO:827, and an HVR-L3 comprising the amino acid sequence of SEQ ID NO:851.
|